PSA DOUBLING TIME SURVIVAL RATE SERIES

The studyД«eing retrospective and the low number of patients included in thisД¬ohort can be the main weaknesses of this study. Rate to docetaxel chemotherapy was found to be a valuable parameter. By means of overall survival, the clinical stage at the time ofДiagnosis was the best predictive tool for our cohort. PSAДoubling time is not a useful predictive tool for predicting response toДocetaxel. The most significant parameter that affects the PSA doubling time was the clinical stage at the time of diagnosis. The best PSA response rate to docetaxel chemotherapy being over or under 50%. Statistically significant prognostic parameter affecting overall survival was After the onset ofДocetaxel, PSA response to therapy and overall survival rates were analyzed toДЇigure out if these parameters were related to PSA doubling time. Metastatic prostate cancer that were given at least 4 cycles of docetaxelД¬hemotherapy between 20 were evaluated. Retrospectively, 70 patients who had hormone refractory To question the value of the PSA response toД¬hemotherapy. Predict the patients who will benefit from docetaxel chemotherapy most, and also We tried to find out if the PSA doubling time helps us to The prognostic factors to determine this response are Start or discontinue chemotherapy for patients with castration resistant Steven Tucker for his valuable input in the review and testing of this calculator.In the targeted therapy era, it is critical to know the certain points to In addition to the lead investigator, Ashutosh Tewari, MD, the following individuals contributed to the development of the PSA Recurrence Model (version 2.0): Christine Cole Johnson, PhD Mutta Issa, MD Rizk El-Galley, MD Hans Stricker, MD James Peabody, MD Julio Pow-Sang, MD Aseem Shukla, MD Zev Wajsman, MD Mark Rubin, MD, John Wei, MD, James Montie, MD, Chris Porter, MD, Michael Harris, MD, Raymond Demers, MD, MPH, Dawn E. Once no further variables met the entry criterion, first order interactions among the final set of model variables were computed and tested for forward stepwise inclusion.Д«y entry of few routinely used parameters, the model correctly identified 76% of the patients who developed a recurrence in the validation set. A p-value of 0.05 or less was required for a variable to be added to the model. Forward variable selection was used with the training dataset to identify a multivariable model for recurrence-free survival. The data set was divided into a training dataset with 1195 patients and a test dataset with 624 patients. Lymph node positive patients were not included in this series.

PSA DOUBLING TIME SURVIVAL RATE SERIES

In our series 64% of patients had organ-confined cancer, 33% positive margin and 14% had seminal vesicle invasion. Eighty percent had clinical stage T2 and 5% T3. Mean length of follow-up was 41.5 months and 67% patients had Gleason scores 5-7. The mean patient age was 68.4 years and mean PSA before surgery was 11.6 ng/mL.

Proportional hazards regression analysis was used to model recurrence as a function of age, race, baseline PSA, pathologic tumor stage, seminal vesicle involvement, margin status, Gleason score and perineural invasion in the final pathology. These patients did not receive adjunct hormonal therapy or radiation treatment prior to developing PSA recurrence. Data from 2,065 men with localized prostate cancer treated with radical prostatectomy at the participating medical institutions between 1992-1999 were analyzed. The study design was a multi-institutional retrospective cohort study. Ashutosh Tewari and his colleagues at the Josephine Ford Cancer Center. This calculator was developed as part of a study conducted by Dr. The objective of this study was to estimate risk for PSA recurrence at 7 years following radical prostatectomy based on preoperative PSA level, clinical stage, biopsy Gleason score, and pathological stage in men with localized prostate cancer. We have developed a model for calculating such risk, which accounts for various tumor characteristics. Physicians and patients need guidance in estimating the risk for recurrence in an individual patient. Thirty to forty percent develop recurrence of serum prostate specific antigen (PSA) in 5-10 years. Tewari's research on prostate cancer also includes robotic surgery to remove the prostate with faster healing and fewer complications.ДЄpproximately 40,000 men undergo radical prostatectomy for the treatment of clinically localized prostate cancer in USA every year. Ash Tewari of Cornell Department of Urology. This calculator has been developed to predict whether a man undergoing radical prostatectomy as primary treatment for clinically localized prostate cancer will have a PSA recurrence of his prostate cancer.

Psa doubling time survival rate